Mark Bachleda - 09 Jun 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Reporting relationship: Director
Issuer ticker: LYEL
Reported as of: 09 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2025, 17:48:27 UTC
Prior SEC filing: 20 Mar 2023
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Charles Newton as Attorney-in-Fact

Key filing fact

Mark Bachleda filed Form 4 for Lyell Immunopharma, Inc. (LYEL) on 11 Jun 2025.

Key facts

This page summarizes Mark Bachleda's Form 4 filing for Lyell Immunopharma, Inc. (LYEL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2025, 17:48.

Change

Previous filing in this sequence was filed on 20 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001887762 Primary reporting owner

Bachleda Mark

Relationship: Director
Address: C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO
Signature: /s/ Charles Newton as Attorney-in-Fact
Signature date: 11 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LYEL transaction Derivative

Option (right to buy)

Award

Transaction value: $0
Shares: +13,000
Change %
Price: $0.000000
Shares after: 13,000
Date: 09 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,000
Exercise price: $12.47
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/36th of the shares of Common Stock subject to the option shall vest on a monthly basis following the grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month), subject to the Reporting Person remaining in service as a director through the applicable vesting date.